# US 2014/0154216 A1 · Virus strains

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0154216 A1
- Document ID: US20140154216A1
- Status: Published application
- Kind: A1
- Application number: 14/175,855
- Filed: 2014-02-07
- Published: 2014-06-05
- Earliest claimed: 2000-01-21
- Assignees: Amgen Inc.
- Applicants: Amgen Inc.
- Inventors: Robert S. COFFIN
- Web page: https://patentgrep.com/patent/US20140154216A1

## CPC

- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 35/763: Herpes virus
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/02: for peripheral neuropathies
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/04: Immunostimulants
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 15/86: Viral vectors
- C12N 15/869: Herpesviral vectors
- A61K 2039/55516: {Proteins; Peptides}
- A61K 2039/55522: {Cytokines; Lymphokines; Interferons}
- C12N 2710/16021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2710/16033: Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
- C12N 2710/16632: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
- C12N 2710/16643: viral genome or elements thereof as genetic vector
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to non-laboratory virus strains, for example of herpes viruses such as HSV, with improved oncolytic and/or gene delivery capabilities as compared to laboratory virus strains.

## Claims

### Claim 1

Use of a modified, oncolytic, non-laboratory virus strain in the manufacture of a medicament for the oncolytic treatment of cancer.

### Claim 2 (depends on 1)

Use according to claim 1 wherein said non-laboratory strain: (a) has undergone one year or less in culture since isolation of its unmodified precursor strain from its host, or (b) has undergone 100 or less cycles of serial passage since isolation of its 10 unmodified precursor strain from its host, or (c) has a greater ability than a reference laboratory strain with equivalent modifications to infect or replicate in a tumour cell, to kill tumour cells, or to spread between cells in tissue, or (d) has substantially the ability of its unmodified precursor strain in respect of 15 one or more of the properties defined in (c).

### Claim 3 (depends on 2)

Use according to claim 2 wherein, in (c), said greater ability is a statistically significantly greater ability; or wherein, in (d), substantially the ability is the same ability or an ability not statistically significantly different.

### Claim 4 (depends on 1)

Use according to claim 1 wherein said non-laboratory virus strain is a strain of a herpes virus, adenovirus, picornavirus, retrovirus or alphavirus.

### Claim 5 (depends on 4)

Use according to claim 4 wherein said non-laboratory virus strain is a strain of a herpes virus.

### Claim 6 (depends on 5)

Use according to claim 5 wherein said non-laboratory virus strain is a strain of a herpes simplex virus (HSV).

### Claim 7 (depends on 6)

Use according to claim 6 wherein said HSV strain is a strain of HSV 1 or HSV2.

### Claim 8 (depends on 7)

Use according to claim 7 wherein said HSV strain is modified such that it lacks one or more of a functional ICP34.5-encoding gene, a functional ICP6-encoding gene, a functional glycoprotein H-encoding gene, or a functional thymidine kinase-encoding gene; or, in a non-HSV strain, the virus lacks a 5 functional gene equivalent to one of said HSV genes.

### Claim 9 (depends on 5)

Use according to claim 5 wherein the non-laboratory virus strain is an HSV strain and the virus lacks a functional ICP34.5-encoding gene.

### Claim 10 (depends on 9)

Use according to claim 9 wherein the non-laboratory virus strain further lacks a functional ICP47 gene.

### Claim 11 (depends on 1)

Use according to claim 1 wherein said non-laboratory virus strain further comprises a heterologous gene.

### Claim 12 (depends on 11)

Use according to claim 11 wherein said heterologous gene is a gene capable of modifying immune responses.

### Claim 13 (depends on 12)

Use according to claim 12 wherein said heterologous gene capable of modifying immune responses encodes an immune stimulatory polypeptide or another gene product capable of modifying immune responses, a prodrug activator, a tumour suppressor or a pro-apoptotic gene product.

### Claim 14 (depends on 13)

Use according to claim 13 wherein said immune stimulatory polypeptide is granulocyte macrophage colony-stimulating factor (GMCSF), another cytokine or chemokine, RANTES, 137.1 or 137.2 or ILI 2, or wherein the prodrug activator is nitroreductase or cytochrome p450, or wherein the tumour suppressor is p53.

### Claim 15 (depends on 1)

Use according to claim 1 wherein the non-laboratory strain is an HSV strain and the reference strain is HSVI strain 17+, HSVI strain F or HSV1 strain KOS with equivalent modifications to the non-laboratory strain.

### Claim 16

Use of a modified, replication incompetent, non-laboratory virus strain comprising a heterologous gene in the manufacture of a medicament for the delivery of said gene to a subject.

### Claim 17 (depends on 16)

Use according to claim 16 wherein said non-laboratory virus strain: (a) has undergone one year or less in culture since isolation of its unmodified precursor strain from its host, or (b) has undergone 100 or less cycles of serial passage since isolation of its unmodified precursor strain from its host, or (c) has a greater ability than a reference laboratory strain with equivalent modifications to infect a target cell, or (d) has a greater ability than a reference laboratory strain with equivalent modifications, to infect a neuron, to spread between cells in nervous tissue, to be transported within an axon, to infect a dendritic cell or to induce an immune response, or (e) has substantially the ability of its unmodified precursor strain in respect of one or more of the properties defined in (c) or (d).

### Claim 18 (depends on 17)

Use according to claim 17 wherein, in (c), a greater ability is a statistically significantly greater ability; or, in (d), substantially the ability is the same ability or an ability not statistically significantly different.

### Claim 19 (depends on 16)

Use according to claim 16 wherein the non-laboratory virus strain is selected from the group consisting of a herpes virus, adenovirus, picornavirus, retrovirus or alphavirus.

### Claim 20 (depends on 19)

Use according to claim 19 wherein in an HSV strain, the virus is modified such that it lacks one, two, three or all of a functional ICP27-encoding gene, a functional ICP4-encoding gene, a functional ICPO-encoding gene, or a functional ICP22-encoding gene; or, in an non-HSV strain, the virus lacks a functional gene equivalent to one of said HSV genes; and/or, in an HSV strain, the virus lacks a functional vmw65 gene due to a mutation in said gene which abolishes its transcriptional-activation activity; or in a non-HSV strain, the virus lacks a functional gene equivalent to vmw65 due to a mutation in said gene which abolishes its transcriptional-activation activity.

### Claim at position 21

21-40. (canceled)

### Claim 41

A method of producing a modified non-laboratory virus strain comprising:
(i) providing a non-laboratory strain of a virus; (ii) modifying it to render it replication incompetent and, (iii) inserting a heterologous gene.

### Claim 42

(canceled)

### Claim 43

A modified, oncolytic, non-laboratory virus strain wherein the virus strain is selected from the group consisting a herpes virus, adenovirus, picornavirus, retrovirus or alphavirus.

### Claim 44

A modified non-laboratory virus strain comprising a heterologous gene.

### Claim at position 26

45-55. (canceled)

### Claim 56 (depends on 43)

A pharmaceutical composition comprising a virus of claim 43.

### Claim 57 (depends on 43)

A virus according to claim 43 for use in the treatment of the human or animal body.

### Claim 58

(canceled)

### Claim 59 (depends on 16)

A method of delivering a gene to an individual in need thereof by administering to said individual an effective amount of a virus as defined in claim 16.

### Claim 60 (depends on 2)

A method of treating or preventing a peripheral nervous system disorder by administering to a peripheral nerve of an individual in need thereof an effective amount of a virus as defined in claim 2.

### Claim 61 (depends on 23)

A method of treating or preventing a central nervous system disorder comprising administering to an individual in need thereof a virus as defined in claim 23.
